Skip to content

Chemotherapy prior to surgery to preserve mandible(jaw bone) for squamous cell cancer of oral cavity

The role of neoadjuvant chemotherapy for mandibular preservation in locally advanced operable squamous cell carcinoma of the oral cavity. - NACTMPT

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/11/006396
Enrollment
68
Registered
2015-11-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Locally advanced borderline operable sqamous cell carcinomas of oral cavity

Interventions

Intervention1: Not applicable: not applicable Intervention2: na: na Intervention3: Neo Adjuvant Chemotherapy: Two cycles of 3 drug Neo adjuvant chemotherapy followed by surgery and adjuvant chemoradia

Sponsors

DAECTC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Previously untreated and biopsy proven stage III and IV squamous cell carcinoma of oral cavity (T3, T4 � N 3cm) requiring segmental mandibular resection. 2. Performance status � 0 or 1(ECOG) or KPS 80 or more. 3. Age - 18 years. 4. Adequate organ function � Normal bone marrow function (Hemoglobin 8 gm/dL, Total leucocyte count 3000/cumm, Absolute neutrophil count 1500/cumm, platelet count 100,000/cumm), normal renal function (normal serum creatinine and calculated creatinine clearance 60ml/min), normal liver function tests (Total Bilirubin �not more than 2 mg/dL, transaminases 5 times upper limit of normal, serum albumin 3 gm/dL) 5. No history of underlying medical disease which might interfere with systemic therapy.

Exclusion criteria

Exclusion criteria: 1. Gross mandibular invasion. 2. Females with childbearing potential should be willing to use contraception. Pregnant females will not be enrolled. 3. Patients unwilling to give written informed consent.

Design outcomes

Primary

MeasureTime frame
Primary Outcome: Mandible Preservation ratesTimepoint: 2 years

Secondary

MeasureTime frame
Secondary Outcome: 1)Quality of Life 2)Overall Survival 3)Disease Free SurvivalTimepoint: 2 years

Countries

India

Contacts

Public ContactDr Devendra Chaukar

TATA MEMORIAL HOSPITAL

dchaukar@gmail.com02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 18, 2026